In the claims:

1. (Currently Amended) A method of treating ~~the psychophysiological effects of stress including~~ anxiety comprising the step of applying to the central nervous system a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV (DP IV) enzyme ~~or of DP IV-like enzyme~~ whereby enzymatic activity of said enzyme is reduced.

2. (Currently Amended) A method for reducing degradation of the endogenous CNS-localized neuropeptide Y (NPY) ~~and other substrates sharing similar properties as neuropeptide Y~~ for the treatment of ~~psychophysiological effects of stress~~ anxiety, comprising the step of applying to the central nervous system a therapeutically effective amount of a competitive inhibitor of the dipeptidyl peptidase (DP IV) ~~or of DP IV - like enzyme~~.

3. (Currently Amended) The method of claim 1 wherein ~~application of~~ said inhibitor ~~results in therapy of psychosomatic, depressive and neuropsychiatric diseases~~ is selected from the group consisting of N-(N`-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine ~~anxiety disorders, depression, insomnia, chronic fatigue, schizophrenia, epilepsy, eating disorders, spasm and chronic pain~~.

4. (Previously Presented) The method of claim 1 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

5. (Currently Amended) The method of claim 1 wherein said inhibitor is formulated in combination with NPY ~~as prodrugs of the free inhibitors~~.

6. (Previously Presented) The method of claim 1 wherein said inhibitor of dipeptidyl peptidase IV is applied parenterally, enteraly, orally, by inhalation or suppository.

7. (Previously Presented) The method of claim 2 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

8. (Cancelled)

9. (Currently Amended) The method of claim 3 wherein said inhibitor is formulated as prodrug [[s]]of the free inhibitors.

10. (Previously Presented) The method of claim 2 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.

11. (Previously Presented) The method of claim 3 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.

12. (Previously Presented) The method of claim 4 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.

13. (Currently Amended) The method of claim ~~8~~ 5 wherein said DP IV-inhibitor in combination with NPY is applied parenterally, enteraly, orally, by inhalation or suppository.

14. (New) The method of claim 2, wherein said DP IV-inhibitor is selected from the group consisting of N-(N`-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.

15. (New) The method of claim 5, wherein said DP IV-inhibitor is selected from the group consisting of N-(N`-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.